Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 101Terminated 30Recruiting 14Active not recruiting 12Withdrawn 8Unknown 7Not yet recruiting 2No longer available 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 8Lymphoid 3Myeloid 2Other neoplasm 1CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1

Interventions

Specimen Handling 3Biopsy 3venetoclax 2luspatercept 2Tacrolimus 2Lymphatic Irradiation 2Imatinib Mesylate 2Busulfan 2Azacitidine 2trametinib 1tagraxofusp 1selinexor 1peginterferon alfa-2b 1olutasidenib 1nilotinib 1flumatinib 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1dabrafenib 1Tyrosine Kinase Inhibitors 1Thiotepa 1Spectroscopy, Near-Infrared 1Sirolimus 1Single-Cell Gene Expression Analysis 1Resistance Training 1Receptors, Antigen, T-Cell 1Quality of Life 1Pleurodesis 1Phlebotomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Busulfan × Myeloid × Clear all
NCT07565220 2026-05-04

Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

University of Pittsburgh

Phase 1 Not yet recruiting
48 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04451200 2020-11-17

BUSEQ

Institut Paoli-Calmettes

Phase 2 Not yet recruiting
82 enrolled
Myeloid

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡